Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News IO Biotech Inc IOBT

Healthcare Biotechnology
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IOBT)

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

GlobeNewswire 3 days ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

GlobeNewswire 9 days ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

GlobeNewswire 13 days ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire March 6, 2024

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

GlobeNewswire March 5, 2024

IO Biotech to Present at 44th Annual Cowen Health Care Conference

GlobeNewswire February 26, 2024

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

GlobeNewswire December 21, 2023

IO Biotech Announces 2023 Third Quarter Results

GlobeNewswire November 13, 2023

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

GlobeNewswire November 13, 2023
View More News ››

Opinion & Analysis (NDAQ:IOBT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IOBT)

Be the first to post on this bullboard.

Heritage Mining Ltd.

Heritage Mining Ltd.

Heritage Mining Ltd. is focused on acquiring and developing Tier-1 advanced stage precious and base metal exploration ...
View More »